Transgene is designing and developing next-generation immunotherapeutics against cancer
First positive data
from Phase I clinical trials
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
One patient, one cancer, one vaccine
With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform.
A new generation of products
These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.
A therapeutic vaccine in Phase II
TG4001 targets HPV-induced anogenital cancers.